Basophil responsiveness in chronic urticaria

Current Allergy and Asthma Reports

Volumn 9, Issue 4, 2009, Pages 286-290

  Saini, Sarbjit S ^a  

^a JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLERGIC REACTION; ANTIGEN ANTIBODY REACTION; BASOPHIL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CHRONIC URTICARIA; CROSS LINKING; DEGRANULATION; EOSINOPHIL; HISTAMINE RELEASE; HUMAN; IDIOPATHIC DISEASE; INFLAMMATION; INFLAMMATORY INFILTRATE; MAST CELL; NEUTROPHIL; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; TH1 CELL; TH2 CELL;

BASOPHILS; CELL DEGRANULATION; CHRONIC DISEASE; HISTAMINE; HUMANS; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; MAST CELLS; RECEPTORS, IGE; URTICARIA;

EID: 68349092665     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-009-0040-3     Document Type: Review

References (46)

1. Greaves M: Chronic urticaria. J Allergy Clin Immunol 2000, 105: 664-672.
2. Kaplan AP: ChPonic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004, 114: 465-474.
3. Toubi E, Kessel A, Avshovich N, et al.: Clinical and laboratory parameters in predicting chronic urticaria duration: A prospective study of 139 patients. Allergy 2004, 59: 869-873.
4. Grob JJ, Revuz J, Ortonne JP, et al.: Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005, 152: 289-295.
5. O'Donnell BF, Lawlor F, Simpson J, et al.: The impact of chronic urticaria on the quality of life. Br J Dermatol 1997, 136: 197-201.
6. Delong LK, Culler SD, Saini SS, et al.: Annual direct and indirect costs of chronic idiopathic urticaria: A cost analysis of fifty non-immunocompromised patients. Arch Dermatol 2008, 144: 35-39.
7. Smith CH, Kepley C, Schwartz LB, Lee TH: Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol 1995, 96: 360-364.
8. Jacques P, Lavoie A, Bedard PM, et al.: Chronic idiopathic urticaria: profiles of skin mast cell histamine release during active disease and remission. J Allergy Clin Immunol 1992, 89: 1139-1143.
9. Cohen RW, Rosenstreich DL: Discrimination between urticaria-prone and other allergic patients by intradermal skin testing with codeine. J Allergy Clin Immunol 1986, 77: 802-807.
10. Ying S, Kikuchi Y, Meng Q, et al.: TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: Comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002, 109: 694-700.
11. Sabroe RA, Poon E, Orchard GE, et al.: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: Comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999, 103: 484-493.
12. Caproni M, Volpi W, Macchia D, et al.: Infiltrating cells and related cytokines in lesional skin of patients with chronic idiopathic urticaria and positive autologous serum skin test. Exp Dermatol 2003, 12: 621-628.
13. Gruber BL, Baeza ML, Marchese MJ, et al.: Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988, 90: 213-217.
14. Hide M, Francis DM, Grattan CE, et al.: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993, 328: 1599-1604.
15. Brodell LA, Beck LA, Saini SS: Pathophysiology of chronic urticaria. Ann Allergy Asthma Immunol 2008, 100: 291-297.
16. Sheikh J: Autoantibodies to the high-affinity IgE receptor in chronic urticaria: How important are they? Curr Opin Allergy Clin Immunol 2005, 5: 403-407.
17. Karasuyama H, Mukai K, Tsujimura Y, Obata K: Newly discovered roles for basophils: A neglected minority gains new respect. Nat Rev Immunol 2009, 9: 9-13.
18. Mukai K, Obata K, Tsujimura Y, Karasuyama H: New insights into the roles for basophils in acute and chronic allergy. Allergol Int 2009, 58: 11-19.
19. Obata K, Mukai K, Tsujimura Y, et al.: Basophils are essential initiators of a novel type of chronic allergic inflammation. Blood 2007, 110: 913-920.
20. Grattan CE, Dawn G, Gibbs S, Francis DM: Blood basophil numbers in chronic ordinary urticaria and healthy controls: Diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy 2003, 33: 337-341.
21. Caproni M, Giomi B, Volpi W, et al.: Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol 2005, 114: 284-292.
22. Schleimer RP, Lichtenstein LM, Gillespie E: Inhibition of basophil histamine release by anti-inflammatory steroids. Nature 1981, 292: 454-455.
23. Charlesworth EN, Kagey-Sobotka A, Schleimer RP, et al.: Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. J Immunol 1991, 146: 671-676.
24. Grattan CE, Walpole D, Francis DM, et al.: Flow cytometric analysis of basophil numbers in chronic urticaria: Basopenia is related to serum histamine releasing activity. Clin Exp Allergy 1997, 27: 1417-1424.
25. Greaves MW, Plummer VM, McLaughlan P, Stanworth DR: Serum and cell bound IgE in chronic urticaria. Clin Allergy 1974, 4: 265-271.
26. Kern F, Lichtenstein LM: Defective histamine release in chronic urticaria. J Clin Invest 1976, 57: 1369-1377.
27. Sabroe RA, Francis DM, Barr RM, et al.: Anti-Fc(episilon)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria. J Allergy Clin Immunol 1998, 102: 651-658.
28. Luquin E, Kaplan AP, Ferrer M: Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli. Clin Exp Allergy 2005, 35: 456-460.
29. Vonakis BM, Vasagar K, Gibbons J, et al.: Basophil FceRI histamine release parallels expression of Src-homology2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 2007, 119: 441-448.
30. Vasagar K, Vonakis BM, Gober L, et al.: Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exp Allergy 2006, 36: 770-776.
31. Lourenco FD, Azor MH, Santos JC, et al.: Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus. Br J Dermatol 2008, 158: 979-986.
32. Kepley CL, Youssef L, Andrews RP, et al.: Syk deficiency in nonreleaser basophils. J Allergy Clin Immunol 1999, 104: 279-284.
33. Macglashan D, Miura K: Loss of syk kinase during IgE-mediated stimulation of human basophils. J Allergy Clin Immunol 2004, 114: 1317-1324.
34. Macglashan DW Jr: Relationship between spleen tyrosine kinase and phosphatidylinositol 5' phosphatase expression and secretion from human basophils in the general population. J Allergy Clin Immunol 2007, 119: 626-633.
35. Harris SJ, Parry RV, Westwick J, Ward SG: Phosphoinositide lipid phosphatases: Natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes. J Biol Chem 2008, 283: 2465-2469.
36. Kimura T, Sakamoto H, Appella E, Siraganian RP: The negative signaling molecule SH2 domain-containing inositol-polyphosphate 5-phosphatase (SHIP) binds to the tyrosine-phosphorylated beta subunit of the high affinity IgE receptor. J Biol Chem 1997, 272: 13991-13996.
37. Gimborn K, Lessmann E, Kuppig S, et al.: SHIP down-regulates FcepsilonR1-induced degranulation at supraoptimal IgE or antigen levels. J Immunol 2005, 174: 507-516.
38. Huber M, Helgason CD, Damen JE, et al.: The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc Natl Acad Sci U S A 1998, 95: 11330-11335.
39. Vonakis BM, Gibbons S Jr, Sora R, et al.: Src homology 2 domain-containing inositol 5' phosphatase is negatively associated with histamine release to human recombinant histamine-releasing factor in human basophils. J Allergy Clin Immunol 2001, 108: 822-831.
40. Gibbs BF, Rathling A, Zillikens D, et al.: Initial Fc epsilon RI-mediated signal strength plays a key role in regulating basophil signaling and deactivation. J Allergy Clin Immunol 2006, 118: 1060-1067.
41. Leung WH, Bolland S: The inositol 5'-phosphatase SHIP-2 negatively regulates IgE-induced mast cell degranulation and cytokine production. J Immunol 2007, 179: 95-102.
42. Vonakis BM, Saini SS: Syk-deficientbasophils from donors with chronic idiopathic urticaria exhibit a spectrum of releasability. J Allergy Clin Immunol 2008, 121: 262-264.
43. Eckman J, Hamilton RG, Gober LM, et al.: Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies. J Invest Dermatol 2008, 128: 1956-1963.
44. Baker R, Vasagar K, Ohameje N, et al.: Basophil histamine release activity and disease severity in chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2008, 100: 244-249.
45. Morgan M, Khan DA: Therapeutic alternativeA for chronic urticaria: an evidence-based review, part 1. Ann Allergy Asthma Immunol 2008, 100: 403-412.
46. Gober L, Sterba P, Eckman J, Saini S: Effect of anti-IgE (omalizumab) in chronic idiopathic urticaria patients. J Allergy Clin Immunol 2008, 121: S147.